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Sununary 
Interleukin 5 (IL-5), the major factor involved in eosinophil  differentiation,  is produced by T 
cells or mast cells. In the present  study, we found that eosinophils infiltrating the mucosa of 
four patients  with active coeliac disease also express the Ib5 mRNA. No positive signal was 
obtained in normal duodenum tissues and in the cell infiltrate from patients submitted to gluten 
restriction. The identification  of labeled mucosal  cells as eosinophils  relied on their typical 
morphology. Moreover, highly purified blood eosinophils from three out of four patients with 
eosinophilia were also strongly labeled with the Ib5 antisense but not with the corresponding 
sense probe. Together, these results suggest that eosinophils have the capacity to synthesize IL-5, 
which could contribute to paracrine interactions  with T and B cells and, in autocrine fashion, 
locally partidpate, through binding to the Ib5 receptor, to eosinophil differentiation and activation. 
These data might have implications not only in the pathology of coeliac disease but also in other 
diseases associated with eosinophil infiltration. 
I 
L-5 supports the proliferation and terminal differentiation 
of eosinophilic precursors (1) as well as the prolonged sur- 
vival of eosinophils in vitro (2). It is also a potent activator 
of eosinophil functions such as cytotoxicity or mediator re- 
lease (3). The effects of IL-5 on B cells and Ig synthesis have 
been studied in more detail in rodents. Both human and mouse 
II.-5 and Ib6 enhance in vitro IgA secretion from isolated 
routine cells of mucosal origin (4). More recently, it has been 
reported that both IL-5 and IL-6 augment local IgA produc- 
tion in vivo, in the tears of rats (5). However, the effect of 
IL-5 on human B cells remains controversial (6). 
Coeliac disease (CD) is defined as a gluten-sensitive  en- 
teropathy that results in intestinal damage with varying degrees 
of villous atrophy.  Morphometric studies have shown that 
the eosinophil population is markedly expanded in the CD 
mucosa and diminished under gluten restriction (7). Another 
feature of CD is a dense infiltration  of the jejunum by IgA- 
secreting plasma cells and an enhanced production of secre- 
tory IgA antibodies  (8). 
By in situ hybridization, ID5 messenger RNA (mRNA) 
was detected in skin and mucosal bronchial biopsies of pa- 
tients with eosinophil infiltration, but without identification 
of the labeled cells (9, 10). In the present study, we analyze 
by a similar approach the expression of ID5 mRNA in duo- 
denojejunal mucosa from patients with CD. Our results show 
the presence of ID5 mRNA in eosinophils and suggest that 
II,5, classically  produced by T cells, can arise from eosinophils 
and participate to eosinophil activation in CD, as well as in 
other diseases. 
Materials and Methods 
Tusue/~ess/n&.  Biopsy  specimens  were collected  by endoscopy 
from the terminal  duodenum of four patients with clinically  active 
GD. The biopsies showed crypt byperphsia and tom villous at- 
rophy. In two of these patients, biopsy specimens were also ob- 
tained endoscopic.ally  at an inactive  phase of the disease  after treat- 
ment by gluten restriction. Negative controls were samples of 
normal duodenum obtained during investigation  of three patients 
with functional  abdominal  pain. Intestinal  fragments  were  properly 
oriented, fixed immediately  in fresh 4% paraformaldehyde/PBS, 
and processed for paraffin embedding by standard techniques. 
Cell Preparations.  Eosinophils  were purified from the blood of 
four patients with ensinophilia  of ditfcmat etiologies: Hodgkin's 
disease, idiopathic  hypereosinophih'c  syndrome,  systemic  mastocy- 
toffs, and episodic angioedema.  A technique of centrifugation on 
discontinuous metrizamide gradients was used as previously  de- 
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the low density layers, were collected. The degree of eosinophil 
purity was evaluated  by May Grfinwald  Giemsa  differential  counting 
on cytocentrifuged  preparations and reached  between 75% and 95% 
eosinophils. These cells were resuspended at a concentration of 0.8 
x  10  ~ cells/ml of HBSS and loaded on gelatin-coated slides (0.8 
x  10  s cells/slide) by cytocentrifugation.  The cytopreparations 
were immediately fixed for 20 rain in 4% paraformaldehyde and 
stored at  -20~  before being analyzed by in situ hybridization. 
Preparation of Labeled Probes.  The cDNA for human Ib5 and 
IL-6 were subdoned into the Blue Script vector by standard tech- 
niques. Linearized plasmids were used as templates for the syn- 
thesis in vitro of 3SS-labehd KNA probes complementary to the 
cellular IL mKNA (antisense probes). RNA was also transcribed 
from the opposite direction and used as a negative control (sense 
probes). 
In Situ Hybn'dization.  For a given KNA, antisense  or sense  probes 
(4,150 cpm/mm  2) were used and hybridization was performed 
with duodenojejunal biopsies and controls as previously described 
(12). To inhibit  the nonspecific binding  of 3sS, tissues and cells 
were acetylated in triethanolamine (0.1 M) for 5 min and then in 
acetic anhydride,  0.25% triethanolamine for 10 min. Then, to avoid 
nonspecific  binding to eosinophils, prehybridization was carried out 
with a solution containing a nonradiohbeled S-UTP irrelevant  probe 
for at least 2 h at 42~  DTT was added to the hybridization buffer, 
and KNAse A was used for posthybridization washings (13). After 
development of the emulsion, tissue sections or cytospin prepara- 
tions were then stained with May Griinwald Giemsa or Hoechst 
for examination in bright or dark field illumination, respectively. 
Results and Discussion 
In situ  hybridization,  using a 3sS-labeled antisense I1.5 
RNA as the probe, revealed that numerous cells infiltrating 
the mucosa of patients with active CD highly express I1-5 
mRNA. The results of one patient are shown in Fig. 1 A; 
however, a similar label intensity was obtained in the mucosa 
of the three other patients. Dark field illumination (Fig. 1 B) 
confirmed the strong level of hybridization and indicated that 
the positive hybridization signal was mainly located around 
the crypts. Examination of the tissues at a higher magnification 
revealed that the majority of eosinophils infiltrating active 
CD mucosae were significantly labeled with the I1-5 antisense 
probe (Fig.  1 C). The presence of eosinophils in the tissue 
samples was detected by immunohistochemical analysis with 
the mAb EG2, which is directed against eosinophil cationic 
protein (14), on serial sections of each biopsy (data not shown). 
Moreover, a reduced time of incubation before development 
was used in order to more precisely identify the labeled cells, 
eosinophils being characterized by their bilobed nuclei (Fig. 
1 D). Very interestingly, no positive signal was detected with 
the Ib5 antisense probe in the mucosa during remission stage 
of the disease, although infiltrating eosinophils were present 
(Fig.  1 E). Similar negative results were obtained in normal 
duodenum samples.  The absence of hybridization signal, in 
active CD patients,  with  the 3sS-labeled I1-5  sense probe 
(Fig.  1 F) as well as with II,-6 sense or antisense probes (not 
shown) indicated that binding of the I1-5 antisense probe 
was specific. Since the identification of eosinophils relied on 
morphologic criteria alone, we wanted to gain further evi- 
dence that eosinophils can express I1.5 mRNA. Therefore, 
highly purified blood eosinophils (up to 95% purity), were also 
studied by in situ hybridization. The majority of eosinophils 
from three out of four patients spontaneously expressed Ib5 
mRNA (Fig.  1 G) with the highest level of expression in 
eosinophils from a patient with the hypereosinophilic syn- 
drome, whereas no hybridization was detected on eosinophils 
from a patient with episodic angioedema. No positive signal 
was detected with the control Ib5 sense probe on purified 
blood eosinophils from any of these patients  (Fig.  1 H). 
Previous reports have established that I1.5 mRNA expres- 
sion, regarded as being characteristic of activated T cells, can 
be detected in cell populations like mast cells (15) or Reed- 
Sternberg cells (16).  The present data indicate that human 
eosinophils, which have been reported to produce TGF-c~ (13), 
can also synthesize IbS.  It is interesting to note that in all 
cases, eosinophils from tissues  or peripheral blood that ex- 
pressed Ib5 mtLNA were activated. This state of activation 
was suggested by the altered morphological appearance of 
eosinophils detected in the tissues during CD by electron mi- 
croscopy (17). In the case of the blood eosinophils, the selected 
hypodense populations correspond to the activated pheno- 
type, previously characterized by immunological and biochem- 
ical properties (11). 
These new findings raise the possibility that expression by 
eosinophils of Ib5 mRNA might result from an activation 
process due to cell interaction or release of mediators in situ. 
It has been recently reported that expression of TGF-o~ by 
eosinophils might be under microenvironmental regulation 
(13).  It will clearly be of interest to search for the factors 
that influence the expression of IIr  mRNA by eosinophils. 
Among these, cytokines or growth factors,  as well as anti- 
bodies, might be involved. It is known that different regula- 
tory mechanisms exist in mast cells for the transcription of 
differents groups of cytokines; in this model, increased levels 
of II-5 mRNA are obtained by IgE-anti-IgE stimulation (15). 
The identification of I1-5 mRNA, which provides evidence 
of gene expression by eosinophils,  suggests but does not prove 
active synthesis of I1-5.  Preliminary results using an 11-5- 
dependent cell line indicate that 99% pure eosinophils can 
secrete a  significant amount of I1-5  (up to 3  U/2  x  106 
cells). Taken together, these results provide evidence for the 
cellular localization of I1-5 mRNA in activated eosinophils, 
suggesting another role for eosinophils in the immune re- 
sponse.  I1.5 can contribute to paracrine interactions with T 
and B cells. In CD, the local secretion of I1.5 can explain, 
at least in part,  the enhanced synthesis of IgA. Autocrine 
effects of I1-5 can also be discussed,  since I1-5 membrane 
receptors have been described, specially expressed on hypodense 
blood and tissue eosinophils (18). An enhanced secretion of 
I1-5  might  influence the  local  stimulation  of eosinophil 
proliferation, differentiation, and activation. In addition, the 
eosinophil infiltrate observed in CD might be due to the effects 
of I1-5 on eosinophil adhesion molecules recently described 
(19). Two recent reports have suggested the production of 
granulocyte/macrophage colony-stimulating factor and I1-3 
by peripheral blood eosinophils, but only after in vitro stim- 
294  Interleukin  5 Messenger R.NA in Eosinophi|s Figure  1.  Detection  of  IL-5 
mRNA in human eosinophils by in 
situ hybridization.  (A-F) Sections 
of the duodenojejunal mucosa of a 
patient with coeliac disease. (A-D) 
Positive in situ hybridization  with 
a 3sS-labeled antisense IL-5 RNA 
probe. Exposure time was 11 d, ex- 
cept for D (7 d). (B) Dark-field il- 
lumination.  (C) At a higher mag- 
nification,  note  the  presence  of 
positively labeled cells with bilobed 
nuclei. (E) Negative hybridization 
signal with the 11,5 antisense probe 
from the same patient  after treat- 
ment. (F) Negative control with the 
sense IL-5 probe.  Arrows indicate 
eosinophils. (G and/-/) Cytoprepa- 
rations of purified blood eosinophils 
from a patient  with hypereosino- 
philic syndrome. (G) Strong hybrid- 
ization  signal  with  the  IL-5 an- 
tisense probe on the six eosinophils. 
(/-/) Similar preparation treated with 
the Ib5 sense probe. 
ulation with calcium ionophore or ionomycine (20, 21). Our 
data indicate  that tissue eosinophils from patients  with CD 
spontaneously express IL-5 mRNA in a defined pathological 
situation. In addition to their inflammatory and effector func- 
tions, eosinophils may thus serve as a source of growth and 
regulatory  factors having a broad range  of biologic effects. 
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